



AGENDA

“Where we are with phage technology- recent developments and global context”

22 October, 16:00-18:00 Central European Time

Online/ Zoom

- 16:00-16:05** Opening of the webinar, Margareta Przybyła, PhageEU Secretary General
- 16:05-16:10** Opening statement by Prof. Jarosław Dastyk, President of PhageEU, CEO of Proteon Pharmaceuticals S.A.
- 16:10-17:10** **Recent developments in phage technology. Presentations by PhageEU members** followed by Q&A
- **“A bacteriophage product against *Staphylococcus aureus* to treat bovine mastitis”**
Dr. habil. Hansjörg Lehnerr, Senior Manager R&D, PTC Phage Technology Center
 - **“Bacteriophage production for various applications from R&D to the commercial scale”**
Dr. Barbara Hubad, Chief Operating Officer, JAFRAL
 - **“Application of artificial intelligence in characterization of bacteriophage”**
Arkadiusz Guziński, Leader of the Bioinformatics Team, Proteon Pharmaceuticals and AI Manager at PhageAI
- 17:10-17:40** **Update from PhageEU partner organisations**, followed by Q&A
- **“State of play in Canada and Global Clinical Phage Rounds”**
Prof. Med. Gregory German, University of Toronto, Department of Laboratory Medicine and Pathobiology and PhageCanada
 - **“Bringing phage therapy to patients- manufacture of bacteriophages in accordance with Good Manufacturing Practices”**
Dr. Grégory Resch, PhD, Head of the Laboratory of bacteriophages and phage therapy, University Hospital of Lausanne
- 17:40-17:50** **Presentation of PhageEU- mission, goals and structure**, Margareta Przybyła, PhageEU Secretary General
- 17:50-18:00** Closing remarks